THC Biomed Intl Ltd (THCBF) Fair Value & Analysis
Healthcare · US · Market cap $164K
THC Biomed Intl Ltd
THCBF · US
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.1900 to $0.0010 (−99.5%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0010 – $0.0010 · fair‑value band $0.0010 – $0.0010 · the $0.0010 price screens below the $0.0010 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
THC Biomed Intl Ltd (THCBF) currently trades at $0.0010, while our model-based Fair Value estimate is $0.0010 — implying the stock looks roughly 0.1% undervalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $2.2M. Revenue declined 22.1% year over year. It earns a return on equity of -56.5%. Net debt stands at $1.5M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
THC Biomed Intl Ltd. engages in the research, development, production, and sale of cannabis products in Canada. The company offers cannabis consumables, including beverage drinks, gummies, baked goods, pre-rolls, sticks, and clones under the THC Kiss brand name; and genetic strains under the THC BioMed brand name. It also provides dry flowers under the Smoke That Thunders brand name; buds under the Always Hi brand name; and transport solution for young live plants under the Cloneshipper brand name. The company was founded in 2012 and is based in Kelowna, Canada.
Revenue & earnings trend
FY2018 – FY2022 · reported fiscal years
THC Biomed Intl Ltd reported revenue of $2.4M in FY2022 versus $925K in FY2018, a compound +27.6%/yr. Reported net income was −$3.1M in FY2022.
Is THCBF fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is THC Biomed Intl Ltd (THCBF) undervalued?
What is the fair value of THCBF?
What is the quality score of THCBF?
What is the revenue of THC Biomed Intl Ltd (THCBF)?
What is the net profit margin of THCBF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.